SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
J Immunother Cancer
; 11(2)2023 02.
Article
in En
| MEDLINE
| ID: mdl-36808075
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Crocus
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Immunother Cancer
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: